Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 79,350 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 79,350 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $6,419,415.00. Following the completion of the transaction, the chief executive officer now owns 453,894 shares in the company, valued at approximately $36,720,024.60. This trade represents a 14.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

William Lewis also recently made the following trade(s):

• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Down 1.0 %

Insmed stock opened at $79.95 on Friday. The firm has a market capitalization of $14.30 billion, a price-to-earnings ratio of -14.41 and a beta of 1.11. The company’s 50 day simple moving average is $72.79 and its 200 day simple moving average is $73.10. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in INSM. CIBC Asset Management Inc increased its position in shares of Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 149 shares in the last quarter. Abel Hall LLC increased its holdings in shares of Insmed by 4.7% in the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 151 shares in the last quarter. Commerce Bank increased its holdings in shares of Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 163 shares in the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. Finally, M&T Bank Corp lifted its holdings in shares of Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 166 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have weighed in on INSM shares. Guggenheim boosted their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Morgan Stanley upped their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.